BA.3.2.* has been shown to be preferentially infecting children.
Across Europe, 18 countries report Patient age data with their samples.
Among children (0-17), BA.3.2.* was at 65% (n=99), vs 24% among adults (n=157), so a ~3X higher rate among children.
🧵


